What age is the bivalent cervical cancer vaccine suitable for?

The bivalent cervical cancer vaccine is suitable for women aged 9-45. The bivalent HPV vaccine is mainly used to prevent cervical cancer caused by HPV16 and HPV18 virus infection. The vaccination age must be determined according to the vaccine instructions and the recommendations of the local health department.

The World Health Organization recommends that females aged 9-14 who have not had sexual intercourse be the first group to be vaccinated. At this time, the immune system's antibody response to the vaccine is stronger. The instructions for the bivalent HPV vaccine approved in my country show that women aged 9-45 can be vaccinated. Among them, women aged 9-14 can use a two-dose vaccination procedure, and those over 15 years old need to be vaccinated with three doses. For women under 26 years old, the vaccine provides better protection because this age group may not have been exposed to high-risk HPV viruses. Vaccination before the age of 45 can still provide some protection, but the immune response may weaken with age. There is no need to undergo HPV screening before vaccination, but vaccination is still recommended for those infected with HPV to prevent other types of infections. Women during menstruation and lactation can be vaccinated normally, but vaccination should be postponed during pregnancy.

Reactions such as pain, redness, swelling or low-grade fever at the injection site may occur after vaccination, which usually resolve spontaneously in 2-3 days. After completing the full course of vaccination, you still need to undergo regular cervical cancer screening because the vaccine cannot prevent all high-risk HPV types. Daily care should be taken to keep the perineum clean, avoid multiple sexual partners, use condoms and other protective measures. If severe allergic reactions or persistent high fever occur after vaccination, you should seek medical treatment in time.